Negative in Ames, in vitro chromosomal aberration and in vivo rat micronucleus assays
“Adagrasib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and was not genotoxic in an in vitro chromosomal aberration assay or an in vivo micronucleus assay in rats.”
“Dedicated carcinogenicity studies were not conducted with adagrasib, as they are not needed to support the use of a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
No fertility, early embryonic or PPND studies (ICH S9); rat and rabbit EFD conducted
“DRF and definitive EFD studies were performed in Wistar rat and NZW rabbits. No fertility, early embryonic development or PPND studies were performed. This is considered acceptable as adagrasib is intended for treatment of advanced cancer, and the ICH S9 guideline applies.”
hERG IC50 3.8 uM, about 48-fold above human free Cmax
“Adagrasib inhibited hERG potassium channel currents with an IC50 of 3.8 μM in a safety pharmacology assessment, which is approximately 48-fold higher than the human free steady-state Cmax of ~0.08 μM based on ~98% protein-binding at the recommended dose.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Genotox: Ames
Negative
“In the standard genotoxicity battery, adagrasib was not mutagenic in a bacterial reverse mutation (Ames) assay nor clastogenic in an in vitro micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Genotox: in vitro mammalian
In vitro micronucleus: not clastogenic; endoreduplication increased almost 4% at 9 µg/mL with S9
“In the standard genotoxicity battery, adagrasib was not mutagenic in a bacterial reverse mutation (Ames) assay nor clastogenic in an in vitro micronucleus assay. However, it is noted that following a 3-hour incubation of cells with adagrasib in the presence of S9, there was increased endoreduplication by almost 4% at 9 μg/mL.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative
“An in vivo bone marrow micronucleus study in rats was unremarkable.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity model
Not conducted: not needed for advanced cancer indication
“Dedicated carcinogenicity studies were not conducted with adagrasib, as they are not needed to support the use of a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Carcinogenicity timing
Not conducted; not needed for advanced cancer (ICH S9)
“The FDA’s Assessment: The FDA agrees that carcinogenicity studies are not needed to support the use of adagrasib in the currently proposed indication per ICH S9.”
✓ VerifiedFDA multi-discipline review, p. 74Source ↗
hERG / QT
hERG IC50 3.8 µM, ~48-fold human free Cmax
“Adagrasib inhibited hERG potassium channel currents with an IC50 of 3.8 μM in a safety pharmacology assessment, which is approximately 48-fold higher than the human free steady-state Cmax of ~0.08 μM based on ~98% protein-binding at the recommended dose.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative